Florbetaben PET tracer data to be presented at Alzheimer's Association ICAD 2010

Bayer HealthCare Pharmaceuticals, Inc. today announced that data on the company's investigational PET amyloid imaging tracer Florbetaben (BAY 94-9172) will be presented at the Alzheimer's Association International Conference on Alzheimer's Disease (Alzheimer's Association ICAD) 2010 in Honolulu July 10 – 15.  

The Florbetaben data will be presented in two oral presentations and in a poster presentation during the official Alzheimer's Association ICAD scientific program, as well as in four poster presentations during the Alzheimer's Imaging Consortium (AIC) preconference, for which Bayer is a co-sponsor. The AIC will bring together the world's leading imaging and non-imaging researchers to focus on the clinical application and methodological development of neuroimaging to Alzheimer's disease, other dementias and normal brain aging.

"At Bayer, we are committed to investing in molecular imaging research to help improve the overall quality of diagnosis and patient care," said Barbara Putz, MD, Head of Global Clinical Development, Molecular Imaging, Bayer.  "We are pleased that data on Florbetaben will be the focus of several presentations during this year's ICAD meeting."

The Florbetaben data being presented at the Alzheimer's Association ICAD 2010 are:

SATURDAY, JULY 10, 2010, Alzheimer's Imaging Consortium

IC-P – Imaging Posters Session

11:15 AM – 1:15 PM, 313-C

• IC-P-059 -; Assessment of ABeta deposition in mild cognitive impairment with 18F-Florbetaben.    Kevin Ong et al. 
• IC-P-119 -; A model-based approach to improve intra-individual comparison of clustered amyloid-beta brain PET imaging data: Accounting for overlapping imaging time windows.     Florian Hiemeyer et al.  
• IC-P-121 -; Inter-ethnic comparability of pharmacokinetics of Florbetaben (BAY 94-9172), a beta-amyloid imaging PET agent, as a basis of global development of a diagnostics for Alzheimer's disease.    Michio Senda et al.  
• IC-P-126 -; Objective SUVr Determination using MRI Segmentation Maps in Florbetaben beta-amyloid Brain PET Improves Discrimination of Alzheimer's and Controls.    John Seibyl et al.

 SUNDAY, JULY 11, 2010, Oral Session O1-02 -- Advances in PET Amyloid Imaging    

1:00 - 3:00 PM, Hall 1

• No. 01-02-01 -; Florbetaben for beta-amyloid brain PET in Alzheimer disease - Results of a multicentre phase 2 trial.    Osama Sabri et al.  
• No. 01-02-02 -; 18F-Florbetaben-PET imaging in the differential diagnosis of dementia.    Victor L. Villemagne et al.

MONDAY, JULY 12, 2010, Poster Session P2 -- Monday Posters  

11:30 AM - 1:00 PM, Exhibit Hall

• No. P2-402 -; Influence of ethnic group, age, gender, and tracer mass dose on florbetaben beta-amyloid brain PET results in elderly normal controls. Henryk Barthel et al.